Antibiotic use in neonatal intensive care units and adherence with centers for disease control and prevention 12 step campaign to prevent antimicrobial resistance

Pediatric Infectious Disease Journal

Volumn 28, Issue 12, 2009, Pages 1047-1051

  Patel, Sameer J ^a   Oshodi, Adebayo ^b,c   Prasad, Priya ^d,e   Delamora, Patricia ^f   Larson, Elaine ^a,g   Zaoutis, Theoklis ^d,e   Paul, David A ^b,c   Saiman, Lisa ^a,h  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CHRISTIANA HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g Columbia University School of Nursing ^*  (United States)

^h NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Antibiotic usage; CDC program; Intensive care units; Neonates; Resistance

Indexed keywords

AMIKACIN; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; GENTAMICIN; METRONIDAZOLE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG UTILIZATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN INTENSIVE CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE;

EID: 74049160280     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b12484     Document Type: Article

References (19)

1. Centers for Disease Control and Prevention. 12-Step Program to Prevent Antimicrobial Resistance in Health Care Settings. 2002; Available at: http://www.cdc.gov/drugresistance/healthcare/default.html. Accessed 2008.
2. Banerjee S, Grohskopf LA, Sinkowitz-Cochran RL, et al. National Noso-comial Infections Surveillance System. Pediatric Prevention Network. Incidence of pediatric and neonatal intensive care unit-acquired infections. Infect Control Hosp Epidemiol. 2006;27:561-570.
3. Grohskopf L, Huskins WC, Sinkowitz-Cochran RL, et al. Use of Antimicrobial agents in US neonatal and pediatric intensive patients. Pediatr Infect Dis J. 2005;24:766-773.
4. Jones DA, Pulver BL, Tai B, et al. Glycopeptide prescribing in an Australian tertiary paediatric hospital. J Paediatr Child Health. 2001;37:342-347.
5. Dellinger PE, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Clin Infect Dis. 1994;18:422-427.
6. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249-1272.
7. Edwards FH, Engelman RM, Houck P, et al. The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg. 2006;81:397-404.
8. Bolon MK, Arnold AD, Feldman HA, et al. Evaluating vancomycin use at a pediatric hospital: new approaches and insights. Infect Control Hosp Epidemiol. 2005;26:47-55.
9. Brinsley KJ, Sinkowitz-Cochran RL, Cardo DM. Assessing motivation for physicians to prevent antimicrobial resistance in hospitalized children using the health belief model as a framework. Am J Infect Control. 2005;33:175-181.
10. Brinsley K, Sinkowitz-Cochran R, Cardo D. An assessment of issues surrounding implementation of the Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. Am J Infect Control. 2005;33:402-409.
11. Cosgrove SE, Patel A, Song X, et al. Impact of different methods of feedback to clinicians after postprescription antimicrobial review based on the Centers For Disease Control and Prevention's 12 Steps to Prevent Antimicrobial Resistance Among Hospitalized Adults. Infect Control Hosp Epidemiol. 2007;28:641-646.
12. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America, Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-177.
13. Patel SJ, Larson EL, Kubin CJ, et al. A review of antimicrobial stewardship control strategies in hospitalized and ambulatory pediatric populations. Pediatr Infect Dis J. 2007;26:531-537.
14. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999; 28:1458-1465.
15. Ehl S, Gering B, Bartmann P, et al. C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics. 1997;99:216-221.
16. Franz AR, Bauer K, Schalk A, et al. Measurement of interleukin 8 in combination with C-reactive protein reduced unnecessary antibiotic therapy in newborn infants: a multicenter, randomized, controlled trial. Pediatrics. 2004;114:1-8.
17. Metjian TA, Prasad PA, Kogon A, et al. Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. Pediatr Infect Dis J. 2008;27:106-111.
18. Rubin LG, Sánchez PJ, Siegel J, et al. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices. Pediatrics. 2002;110:e42.
19. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285-291.